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Background
Chronic spontaneous urticaria (CSU) is a condition, last-
ing at least 6 months, where patients experience frequent
episodes of red, itchy hives and/or angioedema with no
apparent external trigger. For approximately 30-50% of
patients this condition can resolve spontaneously but has
been known to persist for years. CSU can have a major
impact on a patient’s quality of life as it can affect daily
activities, sleep, emotional wellbeing and social interac-
tions. In March 2014, omalizumab was approved in
Europe and eight other countries for the treatment of
CSU in patients with inadequate response to H1-antihis-
tamines at approved doses. However, as yet there is no
approved indication for its use in CSU in Canada and the
US. We report on the effectiveness of omalizumab as a
treatment option for difficult-to-treat CSU in our clinic.
Methods
After receiving a diagnosis of CSU with inadequate
response to H1-antihistamines, and oral prednisone,
patients completed a quality of life (QoL) questionnaire
prior to beginning treatment with omalizumab. Patients
were requested to complete the QoL questionnaires every
two weeks throughout the treatment and, in addition,
were monitored closely for clinical response.
Results
A total of 10 patients, who started on omalizumab for
CSU were evaluated. All were taking H1-antihistamines
prior to treatment with 8 out of the 10 patients able to
decrease or stop the use of H1- antihistamines after the
3rd dose of omalizumab.
The results of the questionnaires indicated a 15%
improvement in QoL with an accompanying 18% decrease
in the symptom score. Of the 10 patients, 9 indicated an
overall improvement in their symptoms while only 6 had
an overall improvement in their QoL.
Conclusion
Omalizumab is an effective therapy in difficult-to-treat
CSU in our tertiary community based allergy and asthma
clinic.
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